drugset / Trial / NCT02981576

Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.

NCT02981576 ↗

Phase 1/2 Completed 14 enrolled University of Jordan
RandomizedParallel-groupOpen-labelTreatment

Summary

Spinal Cord Injury (SCI) is a devastating condition that leads to permanent functional and neurological deficits in injured individuals. The limited ability of the Central Nervous System (CNS) to spontaneously regenerate impairs axonal regeneration and functional recovery of the spinal cord. The leading causes are motor-vehicle crashes, sports-associated accidents, falls, and violence-related injuries. Unfortunately, there is still no effective clinical treatment for SCI. In recent years, tissue engineering and regenerative medicine based approaches have been proposed as alternatives for SCI repair/regeneration. Mesnchymal stem cells (MSC) use in SCI showed promising results in several studies. Our aim is to assess and compare the safety and effectiveness of autologous BM-MSC vs autologous AT-MSC in these patients.

Timeline

Start
2016-11
Primary completion
2018-05-05
Completion
2019-01-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Autologous mesenchymal stem cells Cell therapy — Intrathecal

Indications